netFormulary
 Report : Medicines with links to NICE 28/03/2024 23:18:52

[Back]

Report looks at the links table and pulls back all the items in the formulary where there is a link with 'nice.org' in the URL

You can sort this table Medicines Link Name or Link URL by clicking on the title

Selecting the Medicine name will take you to the entry in the formulary, Selecting the Link name will follow the link

 
Medicines/Item Section Status Link Name / Link URL
Abatacept 10.01.03 Formulary NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis
Abatacept 10.01.03 Formulary NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
Abatacept 10.01.03 Formulary NICE TA715: Adalimumab, etanercept, infliximab and abatacept for treating moderate rheumatoid arthritis after conventional DMARDs have failed
Abemaciclib 08.03.04.01 Formulary NICE TA 563: Abemaciclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer
Abemaciclib 08.03.04.01 Formulary NICE TA810: Abemaciclib with endocrine therapy for adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence
Abemaciclib 08.03.04.01 Formulary NICE TA725: Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy
Abiraterone 08.03.04.02 Formulary NICE TA387:Abiraterone for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated
Abiraterone 08.03.04.02 Formulary NICE TA259: Abiraterone for castration resistant prostate cancer
Abrocitinib 13.05.03 Formulary NICE TA814: Abrocitinib, tralokinumab or upadacitinib for treating moderate to severe atopic dermatitis
Acalabrutinib 08.01.05 Formulary NICE TA689: Acalabrutinib for treating chronic lymphocytic leukaemia
Adalimumab 13.05.03 Formulary NICE TA392: Adalimumab for treating moderate to severe hidradenitis suppurativa
Adalimumab 13.05.03 Formulary NICE TA146 Adalimumab for the treatment of adults with psoriasis
Adalimumab 13.05.03 Formulary NICE TA455 Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people
Adalimumab 01.05.03 Formulary NICE TA187: Crohn’s disease - infliximab and adalimumab
Adalimumab 01.05.03 Formulary NICE TA329: Infliximab, adalimumab and golimumab for moderately to severely active ulcerative colitis
Adalimumab 10.01.03 Formulary NICE TA715: Adalimumab, etanercept, infliximab and abatacept for treating moderate rheumatoid arthritis after conventional DMARDs have failed
Adalimumab 10.01.03 Formulary NICE TA199: Psoriatic arthritis
Adalimumab 10.01.03 Formulary NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
Adalimumab 10.01.03 Formulary NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis
Adalimumab 10.01.03 Formulary NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis
Adalimumab 10.01.03 Formulary NICE TA195: Rheumatoid arthritis - after failure of a TNF inhibitor
Adalimumab 11.04.02 Formulary NICE TA460 Adalimumab and dexamethasone for treating non-infectious uveitis
Adefovir Dipivoxil 05.03.03.01 Formulary NICE TA96: Hep B - adefovir dipivoxil and pegylated interferon alpha-2a
Adefovir Dipivoxil 05.03.03.01 Formulary NICE CG165: Hepatitis B (chronic) - incorporates TA96
Adrenaline / epinephrine 03.04.03 Non Formulary NICE CG134: Anaphylaxis: Assessment and referral after emergency treatment
Afatinib 08.01.05 Formulary NICE TA310: Afatinib for treating epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer
Aflibercept 08.01.05 Formulary NICE TA307: Aflibercept in combination with irinotecan and fluorouracil-based therapy for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy
Aflibercept 4mg/0.1ml injection 11.08.02 Formulary NICE TA 305 Aflibercept for treating visual impairment caused by macular oedema secondary to central retinal vein occlusion
Aflibercept 4mg/0.1ml injection 11.08.02 Formulary NICE TA 294 Aflibercept solution for injection for treating wet age‑related macular degeneration
Aflibercept 4mg/0.1ml injection 11.08.02 Formulary NICE TA 346 Aflibercept for treating diabetic macular oedema
Aflibercept 4mg/0.1ml injection 11.08.02 Formulary NICE TA 409: Aflibercept for treating visual impairment caused by macular oedema after branch retinal vein occlusion
Aflibercept 4mg/0.1ml injection 11.08.02 Formulary NICE TA 486: Aflibercept for treating choroidal neovascularisation
Alectinib 08.01.05 Formulary NICE TA536: Alectinib for untreated ALK-positive advanced non-small-cell lung cancer
Alemtuzumab 08.02.03 Non Formulary NICE TA312: Alemtuzumab for relapsing‑remitting multiple sclerosis
Alemtuzumab 08.02.03 Formulary NICE TA312: Alemtuzumab for relapsing‑remitting multiple sclerosis
Alendronic Acid 06.06.02 Formulary NICE TA464 Bisphosphonates for treating osteoporosis
Alirocumab 02.12 Non Formulary NICE TA393: Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia
Alirocumab 02.12 Formulary NICE TA393: Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia
Alitretinoin 13.05.01 Formulary NICE TA177: Alitretinoin for the treatment of severe chronic hand eczema
Alpelisib 08.03.04.01 Formulary NICE TA816: Alpelisib with fulvestrant for treating hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancer
Alteplase 02.10.02 Formulary NICE TA264: Ischaemic stroke (acute) - alteplase
Alteplase 02.10.02 Formulary NICE NG128: Stroke and transient ischaemic attack in over 16s: diagnosis and initial management
Anakinra 10.01.03 Formulary NICE TA685: Anakinra for treating Still’s disease
Anastrozole 08.03.04.01 Formulary NICE CG164: Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer
Andexanet alfa 02.08.02 Formulary NICE TA697: Andexanet alfa for reversing anticoagulation from apixaban or rivaroxaban
Anti-D (Rh0) Immunoglobulin 14.05.03 Non Formulary NICE TA156: Anti-D in pregnant women
Apalutamide 08.03.04.02 Formulary NICE TA740: Apalutamide with androgen deprivation therapy for treating high-risk hormone-relapsed non-metastatic prostate cancer
Apalutamide 08.03.04.02 Formulary NICE TA741: Apalutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer
Apixaban 02.08.02 Formulary NICE TA245: Apixaban for the prevention of venous thromboembolism after total hip or knee replacement in adults
Apixaban 02.08.02 Formulary NICE TA275: Apixaban for preventing stroke and systemic embolism in people with nonvalvular atrial fibrillation
Apixaban 02.08.02 Formulary NICE TA341: Apixaban for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism
Apremilast 10.01.03 Formulary NICE TA433: Apremilast for treating active psoriatic arthritis
Apremilast 13.05.03 Formulary NICE TA419: Apremilast for treating moderate to severe plaque psoriasis
Aripiprazole 04.02.01 Formulary NICE TA213: Aripiprazole for the treatment of schizophrenia in people aged 15 -17 years
Aripiprazole 04.02.01 Formulary NICE TA292: Bipolar disorder (children) - aripiprazole
Arsenic Trioxide 08.01.05 Formulary NICE TA526: Arsenic trioxide for treating acute promyelocytic leukaemia
Asciminib 08.01.05 Formulary NICE TA813: Asciminib for treating chronic myeloid leukaemia after 2 or more tyrosine kinase inhibitors
Asfotase alfa 09.08.01 Formulary NICE HST23: Asfotase alfa for treating paediatric-onset hypophosphatasia
Ataluren 10.02.01 Formulary NICE HST22: Ataluren for treating Duchenne muscular dystrophy with a nonsense mutation in the dystrophin gene
Atezolizumab 08.01.05 Formulary NICE TA584: Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancer
Atezolizumab 08.01.05 Formulary NICE TA638: Atezolizumab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer
Atezolizumab 08.01.05 Formulary NICE TA639: Atezolizumab with nab-paclitaxel for untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancer
Atezolizumab 08.01.05 Formulary NICE TA739: Atezolizumab for untreated PD-L1-positive advanced urothelial cancer when cisplatin is unsuitable
Atezolizumab 08.01.05 Formulary NICE TA525: Atezolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy
Atezolizumab 08.01.05 Formulary NICE TA520: Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapy
Atezolizumab 08.01.05 Formulary NICE TA666: Atezolizumab with bevacizumab for treating advanced or unresectable hepatocellular carcinoma
Atezolizumab 08.01.05 Formulary NICE TA705: Atezolizumab monotherapy for untreated advanced non-small-cell lung cancer
Atezolizumab 08.01.05 Formulary NICE TA823: Atezolizumab for adjuvant treatment of resected non-small-cell lung cancer
Atidarsagene autotemcel 19 Formulary NICE HST18: Atidarsagene autotemcel for treating metachromatic leukodystrophy
Avalglucosidase alfa 09.08.01 Formulary NICE TA821: Avalglucosidase alfa for treating Pompe disease
Avatrombopag 09.01.04 Formulary NICE TA626: Avatrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure
Avatrombopag 09.01.04 Formulary NICE TA853: Avatrombopag for treating primary chronic immune thrombocytopenia
Avelumab 08.02.03 Formulary NICE TA788: Avelumab for maintenance treatment of locally advanced or metastatic urothelial cancer after platinum-based chemotherapy
Avelumab 08.02.03 Formulary NICE TA645: Avelumab with axitinib for untreated advanced renal cell carcinoma
Avelumab 08.02.03 Formulary NICE TA691: Avelumab for treating metastatic Merkel cell carcinoma
Axicabtagene ciloleucel 08.01.05 Formulary NICE TA895: Axicabtagene ciloleucel for treating relapsed or refractory diffuse large B-cell lymphoma after first-line chemoimmunotherapy
Axicabtagene ciloleucel 08.01.05 Formulary NICE TA872: Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies
Axitinib 08.01.05 Formulary NICE TA333: Axitinib for treating advanced renal cell carcinoma after failure of prior systemic treatment
Axitinib 08.01.05 Formulary NICE TA645: Avelumab with axitinib for untreated advanced renal cell carcinoma
Azacitidine 08.01.03 Formulary NICE TA399: Azacitidine for treating acute myeloid leukaemia with more than 30% bone marrow blasts
Azacitidine 08.01.03 Formulary NICE TA218: Azacitidine for myelodysplastic syndromes
Azacitidine 08.01.03 Formulary NICE TA827: Oral azacitidine for maintenance treatment of acute myeloid leukaemia after induction therapy
Baricitinib 10.01.03 Formulary NICE TA681: Baricitinib for treating moderate to severe atopic dermatitis
Baricitinib 10.01.03 Formulary NICE TA466: Baricitinib for moderate to severe rheumatoid arthritis
Baricitinib 13.05.03 Formulary NICE TA681: Baricitinib for treating moderate to severe atopic dermatitis
Baricitinib 13.05.03 Non Formulary NICE TA926: Baricitinib for treating severe alopecia areata
Basiliximab 08.02.02 Formulary NICE TA482: Immunosuppressive therapy for kidney transplant in children and young people
Basiliximab 08.02.02 Formulary NICE TA481: Immunosuppressive therapy for kidney transplant in adults
Bee and Wasp Allergen Extracts 03.04.02 Formulary NICE TA246: Pharmalgen for the treatment of bee and wasp venom allergy
Belimumab 10.01.03 Formulary NICE TA752: Belimumab for treating active autoantibody-positive systemic lupus erythematosus
Belimumab 10.01 Formulary NICE TA397: Belimumab for treating active autoantibody-positive systemic lupus erythematosus
Bempedoic acid 02.12 Formulary NICE TA694 - Bempedoic acid with ezetimibe for treating primary hypercholesterolaemia or mixed dyslipidaemia
Bempedoic acid with ezetimibe 02.12 Formulary NICE TA694 - Bempedoic acid with ezetimibe for treating primary hypercholesterolaemia or mixed dyslipidaemia
Bendamustine 08.01.01 Formulary NICE TA216: Bendamustine for CLL
Benralizumab 03.04.02 Formulary NICE TA565: Benralizumab for treating severe eosinophilic asthma
Berotralstat 03.04.03 Formulary NICE TA738: Berotralstat for preventing recurrent attacks of hereditary angioedema
Bevacizumab 08.01.05 Formulary NICE TA285: Ovarian, fallopian tube and primary peritoneal cancer (recurrent advanced, platinum-sensitive or partially platinum-sensitive) - bevacizumab
Bevacizumab 08.01.05 Formulary NICE TA284:Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer
Bevacizumab 08.01.05 Formulary NICE TA353: Bevacizumab for treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer (terminated appraisal)
Bimekizumab 13.05.03 Formulary NICE TA723: Bimekizumab for treating moderate to severe plaque psoriasis
Bimekizumab 10.01.03 Formulary NICE TA918: Bimekizumab for treating axial spondyloarthritis
Bimekizumab 10.01.03 Formulary NICE TA916: Bimekizumab for treating active psoriatic arthritis
Bivalirudin 02.08.01 Formulary NICE NG185: Acute coronary syndromes
Blinatumomab 08.02 Formulary NICE TA450 Blinatumomab for previously treated Philadelphia-chromosome-negative acute lymphoblastic leukaemia
Blinatumomab 08.02 Formulary NICE TA589: Blinatumomab for treating acute lymphoblastic leukaemia in remission with minimal residual disease activity
Bortezomib 08.01.05 Formulary NICE TA370: Bortezomib for previously untreated mantle cell lymphoma
Bortezomib 08.01.05 Formulary NICE TA129: Multiple myeloma - bortezomib
Bortezomib 08.01.05 Formulary NICE TA311: Bortezomib for induction therapy in multiple myeloma before high-dose chemotherapy and autologous stem cell transplantation
Bortezomib 08.01.05 Formulary NICE TA228: Bortezomib and thalidomide for the first‑line treatment of multiple myeloma
Bosutinib 08.01.05 Formulary NICE TA401: Bosutinib for previously treated chronic myeloid leukaemia
Botulinum Toxin Type A 04.07.04.02 Formulary NICE TA260: Botulinum toxin type A for the prevention of headaches in adults with chronic migraine
Botulinum Toxin Type A injection 04.09.03 Formulary NICE TA605: Xeomin (botulinum neurotoxin type A) for treating chronic sialorrhoea
Brentuximab vedotin 08.01.05 Formulary NICE TA641: Brentuximab vedotin in combination for untreated systemic anaplastic large cell lymphoma
Brentuximab vedotin 08.01.05 Formulary NICE TA478 Brentuximab vedotin for treating relapsed or refractory systemic anaplastic large cell lymphoma
Brentuximab vedotin 08.01.05 Formulary NICE TA577: Brentuximab vedotin for treating CD30-positive cutaneous T-cell lymphoma
Brentuximab vedotin 08.01.05 Formulary NICE TA524 Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma
Brexucabtagene autoleucel 08.01.05 Formulary NICE TA893: Brexucabtagene autoleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 26 years and over
Brigatinib 08.01.05 Formulary NICE TA571: Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after crizotinib
Brigatinib 08.01.05 Formulary NICE TA670: Brigatinib for ALK-positive advanced non-small-cell lung cancer that has not been previously treated with an ALK inhibitor
Brodalumab 13.05.03 Formulary NICE TA511: Brodalumab for treating moderate to severe plaque psoriasis
Brolucizumab 11.08.02 Formulary NICE TA820: Brolucizumab for treating diabetic macular oedema
Brolucizumab 11.08.02 Formulary NICE TA672: Brolucizumab for treating wet age-related macular degeneration
Budesonide 01.05.02 Formulary NICE TA937: Targeted-release budesonide for treating primary IgA nephropathy
Budesonide 01.05.02 Formulary NICE TA708 - Budesonide orodispersible tablet for inducing remission of eosinophilic oesophagitis
Bulevirtide 05.03.03.02 Formulary NICE TA896: Bulevirtide for treating chronic hepatitis D
Burosumab 06.06.02 Formulary NICE HST 8: Burosumab for treating X-linked hypophosphataemia in children and young people
Cabazitaxel 08.01.05 Formulary NICE TA391: Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel
Cabotegravir 05.03.01 Formulary NICE TA757: Cabotegravir with rilpivirine for treating HIV-1
Cabozantinib 08.01.05 Formulary NICE TA849: Cabozantinib for previously treated advanced hepatocellular carcinoma
Cabozantinib 08.01.05 Formulary NICE TA516: Cabozantinib for treating medullary thyroid cancer
Cabozantinib 08.01.05 Formulary NICE TA463 Cabozantinib for previously treated advanced renal cell carcinoma
Cabozantinib 08.01.05 Formulary NICE TA 542: Cabozantinib for untreated advanced renal cell carcinoma
Canagliflozin 06.01.02.03 Formulary NICE TA315: Canagliflozin for type 2 diabetes
Canagliflozin 06.01.02.03 Formulary NICE TA390: Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes
Cannabidiol 04.06 Formulary NICE TA614: Cannabidiol with clobazam for treating seizures associated with Dravet syndrome
Cannabidiol 04.06 Formulary NICE TA615: Cannabidiol with clobazam for treating seizures associated with Lennox–Gastaut syndrome
Cannabidiol 04.08.01 Formulary NICE TA873: Cannabidiol for treating seizures caused by tuberous sclerosis complex
Cannabidiol 04.08.01 Formulary NICE TA614: Cannabidiol with clobazam for treating seizures associated with Dravet syndrome
Cannabidiol 04.08.01 Formulary NICE TA615: Cannabidiol with clobazam for treating seizures associated with Lennox–Gastaut syndrome
Cannabis extract 10.02.02 Formulary NICE NG144: Cannabis-based medicinal products
Capecitabine 08.01.03 Formulary NICE TA191: Gastric cancer (advanced) - capecitabine
Capecitabine 08.01.03 Formulary NICE TA61: Colorectal cancer - capecitabine and tegafur uracil
Capecitabine 08.01.03 Formulary NICE TA100: Colon cancer (adjuvant) - capecitabine and oxaliplatin
Caplacizumab 09.01.04 Formulary NICE TA667: Caplacizumab with plasma exchange and immunosuppression for treating acute acquired thrombotic thrombocytopenic purpura
Capsaicin 10.03.02 Formulary NICE NG226 - Osteoarthritis in over 16s: diagnosis and management
Carfilzomib 08.01.05 Formulary NICE TA695: Carfilzomib with dexamethasone and lenalidomide for previously treated multiple myeloma
Carfilzomib 08.01.05 Formulary NICE TA657: Carfilzomib for previously treated multiple myeloma (COVID-19)
Carmustine 08.01.01 Non Formulary NICE TA121: Glioma (newly diagnosed and high grade) - carmustine implants and temozolomide
Carmustine 08.01.01 Formulary NICE TA121: Glioma (newly diagnosed and high grade) - carmustine implants and temozolomide
Cemiplimab 08.01.05 Formulary NICE TA802: Cemiplimab for treating advanced cutaneous squamous cell carcinoma
Cenobamate 04.08.01 Formulary NICE TA753: Cenobamate for treating focal onset seizures in epilepsy
Ceritinib 08.01.05 Formulary NICE TA395: Ceritinib for previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer
Ceritinib 08.01.05 Formulary NICE TA500: Ceritinib for untreated ALK-positive non-small-cell lung cancer
Certolizumab Pegol 10.01.03 Formulary NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis
Certolizumab Pegol 10.01.03 Formulary NICE TA574: Certolizumab pegol for treating moderate to severe plaque psoriasis
Certolizumab Pegol 10.01.03 Formulary NICE TA 415 - Certolizumab pegol for treating rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor
Certolizumab Pegol 10.01.03 Formulary NICE TA445: Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs
Certolizumab Pegol 10.01.03 Formulary NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
Certolizumab pegol  13.05.03 Formulary NICE TA574: Certolizumab pegol for treating moderate to severe plaque psoriasis
Cetuximab 08.01.05 Formulary NICE TA145: Cetuximab for the treatment of locally advanced squamous cell cancer of the head and neck
Cetuximab 08.01.05 Formulary NICE TA242: Cetuximab for the treatment of metastatic colorectal cancer after first-line chemotherapy: monotherapy or combination chemotherapy
Cetuximab 08.01.05 Formulary NICE TA439 Cetuximab and panitumumab for previously untreated metastatic colorectal cancer
Cetuximab 08.01.05 Formulary NICE TA473 Cetuximab for treating recurrent or metastatic squamous cell cancer of the head and neck (oral cavity)
Chlormethine hydrochloride 08.01.01 Formulary NICE TA720: Chlormethine gel for treating mycosis fungoides-type cutaneous T-cell lymphoma
Ciclosporin 11.08.02.04 Non Formulary NICE TA369 - Ciclosporin for treating eye disease that has not improved despite treatment with artificial tears
Ciclosporin 0.1% (1mg/1ml) Eye Drops 11.04.02 Formulary NICE TA369: Ciclosporin for treating dry eye disease that has not improved despite treatment with artificial tears
Cinacalcet 09.05.01.02 Formulary NICE TA117: Hyperparathyroidism - cinacalcet
Cipaglucosidase alfa (CIPA) 09.08.01 Formulary NICE TA912: Cipaglucosidase alfa with miglustat for treating late-onset Pompe disease
Cladribine 08.01.03 Formulary NICE TA616: Cladribine for treating relapsing–remitting multiple sclerosis
Clopidogrel 02.09 Formulary NICE TA210: Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events
Colistimethate 05.01.07 Formulary TA276:Colistimethate sodium and tobramycin dry powders for inhalation for treating pseudomonas lung infection in cystic fibrosis
Colistimethate inhaler 05.01.07 Non Formulary NICE TA276: Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin
Collagenase 10.03.01 Formulary NICE TA459 Collagenase clostridium histolyticum for treating Dupuytren’s contracture
Crizanlizumab 08.01.05 Formulary NICE TA743: Crizanlizumab for preventing sickle cell crises in sickle cell disease
Crizotinib 08.01.05 Formulary NICE TA406: Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer
Crizotinib 08.01.05 Formulary NICE TA422: Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer
Crizotinib 08.01.05 Formulary NICE TA529: Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer
Dabigatran 02.08.02 Formulary NICE TA327: Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism
Dabigatran 02.08.02 Formulary NICE TA157: Dabigatran etexilate for the prevention of venous thromboembolism after hip or knee replacement surgery in adults
Dabigatran 02.08.02 Formulary NICE TA249: Dabigatran for Stroke prevention in AF
Dabrafenib 08.01.05 Formulary NICE TA321: Dabrafenib for treating unresectable or metastatic BRAF V600 mutation‑positive melanoma
Dabrafenib 08.01.05 Formulary NICE TA396: Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma
Dabrafenib 08.01.05 Formulary NICE TA544: Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma
Dabrafenib 08.01.05 Formulary NICE TA898: Dabrafenib plus trametinib for treating BRAF V600 mutation-positive advanced non-small-cell lung cancer
Dacomitinib 08.01.05 Formulary NICE TA595: Dacomitinib for untreated EGFR mutation-positive non-small-cell lung cancer
Dapafliflozin 02.15 Formulary NICE TA902: Dapagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction
Dapafliflozin 02.15 Formulary NICE TA679: Dapagliflozin for treating chronic heart failure with reduced ejection fraction
Dapagliflozin 06.01.02.03 Formulary NICE TA288: Dapagliflozin in combination therapy for treating type 2 diabetes
Dapagliflozin 06.01.02.03 Formulary NICE TA390: Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes
Dapagliflozin 06.01.02.03 Formulary NICE TA418: Dapagliflozin in triple therapy for treating type 2 diabetes
Dapagliflozin 06.01.02.03 Formulary NICE TA775: Dapagliflozin for treating chronic kidney disease
Daratumumab 08.01.05 Formulary NICE TA783: Daratumumab monotherapy for treating relapsed and refractory multiple myeloma
Daratumumab 08.01.05 Formulary NICE TA763: Daratumumab in combination for untreated multiple myeloma when a stem cell transplant is suitable
Daratumumab 08.01.05 Formulary NICE TA897: Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma
Daratumumab 08.01.05 Formulary NICE TA917: Daratumumab with lenalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is unsuitable
Darbepoetin Alfa 09.01.03 Formulary NICE CG114: Anaemia in chronic kidney disease
Darbepoetin Alfa 09.01.03 Formulary NICE TA323: Erythropoiesis‑stimulating agents during chemotherapy
Daridorexant 04.01.01 Formulary NICE TA922: Daridorexant for treating long-term insomnia
Darolutamide 08.03.04.02 Formulary NICE TA660: Darolutamide with androgen deprivation therapy for treating hormone-relapsed non-metastatic prostate cancer
Darolutamide 08.03.04.02 Formulary NICE TA903: Darolutamide with androgen deprivation therapy and docetaxel for treating hormone-sensitive metastatic prostate cancer
Dasabuvir 05.03.03.02 Non Formulary NICE TA365: Ombitasvir–paritaprevir–ritonavir with or without dasabuvir for treating chronic hepatitis C
Dasatinib 08.01.05 Formulary NICE TA425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
Dasatinib 08.01.05 Formulary NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
Daunorubicin/cytarabine 08.01.03 Formulary NICE TA 552: Liposomal cytarabine–daunorubicin for untreated acute myeloid leukaemia
Decitabine 08.01.03 Non Formulary NICE TA270: Leukaemia (acute myeloid ) - decitabine (terminated appraisal)
Degarelix 08.03.04.02 Formulary NICE TA404: Degarelix for treating advanced hormone-dependent prostate cancer
Denosumab 06.06.02 Formulary NICE TA204: Osteoporotic fractures - denosumab
Denosumab 06.06.02 Formulary NICE TA265: Bone metastases from solid tumours - denosumab: guidance
Deucravacitinib 13.05.03 Formulary NICE TA907: Deucravacitinib for treating moderate to severe plaque psoriasis
Dexamethasone 700 microgram intravitreal implant 11.04.01 Formulary NICE TA460 Adalimumab and dexamethasone for treating non-infectious uveitis
Dexamethasone 700 microgram intravitreal implant 11.04.01 Formulary NICE TA229 Dexamethasone intravitreal implant for the treatment of macular oedema secondary to retinal vein occlusion
Dexamethasone 700 microgram intravitreal implant 11.04.01 Formulary NICE TA824: Dexamethasone intravitreal implant for treating diabetic macular oedema
Dimethyl fumarate 13.05.03 Formulary NICE TA475 Dimethyl fumarate for treating moderate to severe plaque psoriasis
Dimethyl fumarate 08.02.04 Formulary NICE TA320: Dimethyl fumarate for multiple sclerosis
Dinutuximab beta 08.01.05 Formulary NICE TA 538: Dinutuximab beta for treating neuroblastoma
Dipyridamole 02.09 Formulary NICE TA210: Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events
Diroximel fumarate 08.02.04 Formulary NICE TA794: Diroximel fumarate for treating relapsing–remitting multiple sclerosis
Docetaxel 08.01.05 Formulary NICE NG101: Early and locally advanced breast cancer: diagnosis and management
Docetaxel 08.01.05 Formulary NICE TA101: Docetaxel for the treatment of hormone-refractory metastatic prostate cancer
Donepezil 04.11 Formulary NICE TA217: Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer’s disease
Doxorubicin 08.01.02 Formulary NICE TA389 - Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
Dronedarone 02.03.02 Formulary NICE TA197 (Atrial fibrillation - dronedarone)
Dulaglutide 06.01.02.03 Formulary NICE NG18: Diabetes (type 1 and type 2) in children and young people: diagnosis and management
Dupilumab 13.05.03 Formulary NICE TA534: Dupilumab for treating moderate to severe atopic dermatitis
Dupilumab 03.04.02 Formulary NICE TA751: Dupilumab for treating severe asthma with type 2 inflammation
Durvalumab 08.01.05 Formulary NICE TA798: Durvalumab for maintenance treatment of unresectable non-small-cell lung cancer after platinum-based chemoradiation
Eculizumab 09.01.03 Formulary NICE HST 1 - Eculizumab for treating atypical haemolytic uraemic syndrome
Eculizumab 09.01.03 Formulary NICE TA647: Eculizumab for treating relapsing neuromyelitis optica (terminated appraisal)
Eculizumab 09.01.03 Formulary NICE TA636: Eculizumab for treating refractory myasthenia gravis (terminated appraisal)
Edoxaban 02.08.02 Formulary NICE TA355:Edoxaban for preventing stroke/systemic embolism in non‑valvular atrial fibrillation
Edoxaban 02.08.02 Formulary NICE TA354: Edoxaban for treating and for preventing deep vein thrombosis and pulmonary embolism
Elbasvir & grazoprevir 05.03.03.02 Formulary NICE TA413: Elbasvir–grazoprevir for treating chronic hepatitis C
Eliglustat 09.08.01 Formulary NICE HST5 Eliglustat for treating type 1 Gaucher disease
Elosulfase alfa 09.08.01 Formulary NICE HST19 - Elosulfase alfa for treating mucopolysaccharidosis type 4A
Eltrombopag 09.01.04 Formulary NICE TA293: Eltrombopag for treating chronic ITP
Eluxadoline 01.04.02 Non Formulary NICE TA471 Eluxadoline for treating irritable bowel syndrome with diarrhoea
Empagliflozin 06.01.02.03 Formulary NICE TA942: Empagliflozin for treating chronic kidney disease
Empagliflozin 06.01.02.03 Formulary NICE NG18: Diabetes (type 1 and type 2) in children and young people: diagnosis and management
Empagliflozin 06.01.02.03 Formulary NICE TA390: Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes
Empagliflozin 06.01.02.03 Formulary NICE TA336: Empagliflozin for type 2 diabetes
Empagliflozin 02.15 Formulary NICE TA773: Empagliflozin for treating chronic heart failure with reduced ejection fraction
Empagliflozin 02.15 Formulary NICE TA929: Empagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction
Encorafenib 08.01.05 Formulary NICE TA668: Encorafenib plus cetuximab for previously treated BRAF V600E mutation-positive metastatic colorectal cancer
Encorafenib 08.01.05 Formulary NICE TA562: Encorafenib with binimetinib for unresectable or metastatic BRAF V600 mutation-positive melanoma
Entecavir 05.03.03.01 Formulary NICE CG165: Hepatitis B (incorporates TA153)
Entecavir 05.03.03.01 Formulary NICE TA153: Hepatitis B (chronic) - etecavir
Entrectinib 08.01.05 Formulary NICE TA644 Entrectinib for treating NTRK fusion-positive solid tumours
Entrectinib 08.01.05 Formulary NICE TA643: Entrectinib for treating ROS1-positive advanced non-small-cell lung cancer
Enzalutamide 08.03.04.02 Formulary NICE TA316: Enzalutamide for prostate cancer
Enzalutamide 08.03.04.02 Formulary NICE TA377: Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated
Enzalutamide 08.03.04.02 Formulary NICE TA712: Enzalutamide for treating hormone-sensitive metastatic prostate cancer
Eplerenone 02.02.03 Formulary NICE NG106: Chronic heart failure in adults: diagnosis and management
Epoetin alfa 09.01.03 Formulary NICE TA323: Erythropoiesis‑stimulating agents during chemotherapy
Epoetin alfa 09.01.03 Formulary NICE NG203: Chronic kidney disease: assessment and management
Epoetin beta 09.01.03 Formulary NICE TA323: Erythropoiesis‑stimulating agents during chemotherapy
Epoetin beta 09.01.03 Formulary NICE NG203: Chronic kidney disease: assessment and management
Eptinezumab 04.07.04.02 Formulary NICE TA871: Eptinezumab for preventing migraine
Erenumab 04.07.04.02 Formulary NICE TA682: Erenumab for preventing migraine in adults
Eribulin 08.01.05 Formulary NICE TA423: Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens
Erlotinib 08.01.05 Formulary NICE TA258: Erlotinib for the first-line treatment of locally advanced or metastatic EGFR-TK mutation-positive non-small-cell lung cancer
Erlotinib 08.01.05 Formulary NICE TA227: Erlotinib monotherapy for maintenance treatment of non-small-cell lung cancer
Erlotinib 08.01.05 Formulary NICE TA374: Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy
Ertugliflozin 06.01.02.03 Formulary NICE TA583: Ertugliflozin with metformin and a dipeptidyl peptidase-4 inhibitor for treating type 2 diabetes
Ertugliflozin 06.01.02.03 Formulary NICE TA572: Ertugliflozin as monotherapy or with metformin for treating type 2 diabetes
Etanercept 10.01.03 Non Formulary NICE TA199: Psoriatic arthritis
Etanercept 10.01.03 Non Formulary NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
Etanercept 10.01.03 Non Formulary NICE TA35: Adult psoriasis
Etanercept 10.01.03 Non Formulary NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis
Etanercept 10.01.03 Non Formulary NICE TA195: rheumatoid arthritis after the failure of a TNF inhibitor
Etanercept 13.05.03 Formulary NICE TA455 Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people
Etanercept 13.05.03 Formulary NICE TA103: Psoriasis - efalizumab and etanercept
Etanercept 10.01.03 Formulary NICE TA715: Adalimumab, etanercept, infliximab and abatacept for treating moderate rheumatoid arthritis after conventional DMARDs have failed
Etanercept 10.01.03 Formulary NICE TA199: Psoriatic arthritis
Etanercept 10.01.03 Formulary NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for JIA
Etanercept 10.01.03 Formulary NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis
Etanercept 10.01.03 Formulary NICE TA195: Rheumatoid arthritis after the failure of a TNF inhibitor
Etanercept 10.01.03 Formulary NICE TA35: Adult psoriasis
Etanercept 10.01.03 Formulary NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
Etelcalcetide 09.05.01.02 Formulary NICE TA448 Etelcalcetide for treating secondary hyperparathyroidism
Everolimus 08.01.05 Formulary NICE TA449 Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease
Everolimus 08.01.05 Formulary NICE TA432: Everolimus (Afinitor) for advanced renal cell carcinoma after previous treatment
Everolimus 08.01.05 Formulary NICE TA421: Everolimus with exemestane for treating advanced breast cancer after endocrine therapy
Everolimus 08.01.05 Formulary NICE TA348: Everolimus for preventing organ rejection in liver transplantation
Everolimus 08.01.05 Formulary NICE TA481: Immunosuppressive therapy for kidney transplant in adults
Everolimus 08.01.05 Formulary NICE TA482: Immunosuppressive therapy for kidney transplant in children and young people
Everolimus 08.01.05 Formulary NICE TA498: Lenvatinib with everolimus for previously treated advanced renal cell carcinoma
Evolocumab 02.12 Non Formulary NICE TA394: Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia
Evolocumab 02.12 Formulary NICE TA394: Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia
Exenatide prolonged release 06.01.02.03 Non Formulary NICE TA248: MR exenatide
Ezetimibe 02.12 Formulary NICE TA385: Ezetimibe for treating primary heterozygous-familial and non-familial hypercholesterolaemia
Faricimab 11.08.02 Formulary NICE TA800: Faricimab for treating wet age-related macular degeneration
Faricimab 11.08.02 Formulary NICE TA799: Faricimab for treating diabetic macular oedema
Febuxostat 10.01.04 Formulary NICE NG219: Gout: diagnosis and management
Fenfluramine 04.08.01 Formulary NICE TA808: Fenfluramine for treating seizures associated with Dravet syndrome
Filgotinib 01.05.03 Formulary NICE TA792: Filgotinib for treating moderately to severely active ulcerative colitis
Filgotinib 10.01.03 Formulary NICE TA676: Filgotinib for treating moderate to severe rheumatoid arthritis
Filgotinib 10.01.03 Formulary NICE TA792: Filgotinib for treating moderately to severely active ulcerative colitis
Finasteride 5mg tablets 06.04.02 Formulary NICE CG97 Lower urinary tract symptoms: quick reference guide
Finerenone 02.02.03 Formulary NICE TA877: Finerenone for treating chronic kidney disease in type 2 diabetes
Fingolimod 08.02.04 Formulary NICE TA254: Fingolimod for highly active relapsing remitting multiple sclerosis
Fludarabine Phosphate 08.01.03 Formulary NICE TA29: Guidance on the use of fludarabine for B-cell chronic lymphocytic leukaemia
Fludarabine Phosphate 08.01.03 Formulary NICE TA119: Fludarabine monotherapy for the first-line treatment of chronic lymphocytic leukaemia
Fluocinolone 190 microgram intravitreal implant 11.04.01 Formulary NICE TA590: Fluocinolone acetonide intravitreal implant for treating recurrent non-infectious uveitis
Fluocinolone 190 microgram intravitreal implant 11.04.01 Formulary NICE TA301Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema after an inadequate response to prior therapy
Fluocinolone 190 microgram intravitreal implant 11.04.01 Formulary NICE TA613: Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema in phakic eyes after an inadequate response to previous therapy
Fondaparinux 02.08.01 Formulary Venous thromboembolic diseases: diagnosis, management and thrombophilia testing
Foslevidopa/foscarbidopa 04.09.01 Formulary NICE TA934: Foslevodopa–foscarbidopa for treating advanced Parkinson’s with motor symptoms
Fostamatinib 08.01.05 Formulary NICE TA835: Fostamatinib for treating refractory chronic immune thrombocytopenia
Fremanezumab 04.07.04.02 Formulary NICE TA764: Fremanezumab for preventing migraine
Fulvestrant 08.03.04.01 Formulary NICE TA239: Fulvestrant for the treatment of locally advanced or metastatic breast cancer
Galantamine 04.11 Formulary NICE TA217: Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer’s disease
Galcanezumab 04.07.04.02 Formulary NICE TA659: Galcanezumab for preventing migraine
Gefitinib 08.01.05 Formulary NICE TA374: Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy
Gefitinib 08.01.05 Formulary NICE TA192: Lung cancer (non-small-cell, first line) - gefitinib
Gemcitabine 08.01.03 Formulary NICE TA116: Gemcitabine for the treatment of metastatic breast cancer
Gemcitabine 08.01.03 Formulary NICE NG85: Pancreatic cancer in adults: diagnosis and management
Gemcitabine 08.01.03 Formulary NICE TA389: Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
Gemtuzumab ozogamicin 08.01.05 Formulary NICE TA545: Gemtuzumab ozogamicin for untreated acute myeloid leukaemia
Gilteritinib 08.01.05 Formulary NICE TA642: Gilteritinib for treating relapsed or refractory acute myeloid leukaemia
Givosiran 09.08.02 Formulary NICE HST 16: Givosiran for treating acute hepatic porphyria
Glatiramer Acetate 08.02.04 Formulary NICE TA527: Beta interferons and glatiramer acetate for treating multiple sclerosis
Glecaprevir & Pibrentasvir 05.03.03.02 Formulary NICE TA499: Glecaprevir–pibrentasvir for treating chronic hepatitis C
GLIADEL wafer Carmustine 7.6mg 20 Non Formulary NICE TA121: Glioma - carmustine implants and temozolomide
Glofitamab 08.01.05 Formulary NICE TA927: Glofitamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments
Golimumab 10.01.03 Formulary NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis
Golimumab 10.01.03 Formulary NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
Golimumab 10.01.03 Formulary NICE TA220: psoriatic arthritis
Golimumab 10.01.03 Formulary NICE TA497: Golimumab for treating non-radiographic axial spondyloarthritis
Golimumab 01.05.03 Formulary NICE TA329: Infliximab, adalimumab and golimumab for moderately to severely active ulcerative colitis
Guselkumab 13.05.03 Formulary NICE TA521: Guselkumab for treating moderate to severe plaque psoriasis
Guselkumab 10.01.03 Formulary NICE TA815: Guselkumab for treating active psoriatic arthritis after inadequate response to DMARDs
Haloperidol 04.02.01 Formulary NICE NG10: Violence and aggression: short-term management in mental health, health and community settings
Hydroxocobalamin 1mg in 1ml injection 09.01.02 Formulary NICE NG239: Vitamin B12 deficiency in over 16s: diagnosis and management
Ibandronic Acid 06.06.02 Formulary NICE TA464 Bisphosphonates for treating osteoporosis
Ibrutinib 08.01.05 Formulary NICE TA891: Ibrutinib with venetoclax for untreated chronic lymphocytic leukaemia
Ibrutinib 08.01.05 Formulary NICE TA795: Ibrutinib for treating Waldenstrom’s macroglobulinaemia
Ibrutinib 08.01.05 Formulary NICE TA429: Ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation
Ibrutinib 08.01.05 Formulary NICE TA502: Ibrutinib for treating relapsed or refractory mantle cell lymphoma
Icosapent ethyl 02.12 Formulary NICE TA805: Icosapent ethyl with statin therapy for reducing the risk of cardiovascular events in people with raised triglycerides
Idecabtagene vicleucel 08.01.05 Non Formulary NICE TA936: Idecabtagene vicleucel for treating relapsed and refractory multiple myeloma after 3 or more treatments (terminated appraisal)
Idelalisib 08.01.05 Formulary NICE TA359: Chronic lymphocytic leukaemia - Idelalisib
Imatinib 08.01.05 Formulary NICE TA209: Imatinib for the treatment of unresectable and/or metastatic gastrointestinal stromal tumours
Imatinib 08.01.05 Formulary NICE TA326: Imatinib for the adjuvant treatment of gastrointestinal stromal tumours
Imatinib 08.01.05 Formulary NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
Imatinib 08.01.05 Formulary NICE TA425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
Imatinib 08.01.05 Formulary NICE TA70: Guidance on the use of imatinib for chronic myeloid leukaemia
Imatinib 08.01.05 Formulary NICE TA86: Imatinib for the treatment of unresectable and/or metastatic gastro-intestinal stromal tumours
Imlifidase 08.01.05 Formulary NICE TA809: Imlifidase for desensitisation treatment before kidney transplant in people with chronic kidney disease
Inclisiran 02.12 Formulary NICE TA 733 - Inclisiran for treating primary hypercholesterolaemia or mixed dyslipidaemia
Infliximab 01.05.03 Formulary NICE TA187: Crohns disease - infliximab & adalimumab
Infliximab 01.05.03 Formulary NICE TA329: Infliximab, adalimumab and golimumab for moderately to severely active ulcerative colitis
Infliximab 01.05.03 Formulary NICE TA163: Ulcerative colitis (acute manifestations) Infliximab
Infliximab 10.01.03 Formulary NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
Infliximab 10.01.03 Formulary NICE TA199: Psoriatic arthritis
Infliximab 10.01.03 Formulary NICE TA195: Rheumatoid arthritis (after failure of a TNF inhibitor)
Infliximab 10.01.03 Formulary NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis
Infliximab 10.01.03 Formulary NICE TA715: Adalimumab, etanercept, infliximab and abatacept for treating moderate rheumatoid arthritis after conventional DMARDs have failed
Infliximab 13.05.03 Formulary NICE TA134: Infliximab for psoriasis
Inotersen 04.12 Formulary NICE Highly specialised technologies 9: Inotersen for treating hereditary transthyretin amyloidosis
Inotuzumab ozogamicin 08.01.05 Formulary NICE TA541: Inotuzumab ozogamicin for treating relapsed or refractory B-cell acute lymphoblastic leukaemia
Insulin Glargine biosimilar Abasaglar® 06.01.01.02 Formulary NG17: Type 1 diabetes in adults: diagnosis and management
Interferon beta 08.02.04 Formulary NICE TA527: Beta interferons and glatiramer acetate for treating multiple sclerosis
Interferon Beta 08.02.04 Formulary NICE TA527: Beta interferons and glatiramer acetate for treating multiple sclerosis
Interferon Beta 08.02.04 Formulary NICE TA527: Beta interferons and glatiramer acetate for treating multiple sclerosis
Interferon Beta 08.02.04 Formulary NICE TA527: Beta interferons and glatiramer acetate for treating multiple sclerosis
Ipilimumab 08.01.05 Formulary NICE TA268: Ipilimumab for previously treated advanced (unresectable or metastatic) melanoma
Ipilimumab 08.01.05 Formulary NICE TA319: Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma
Ipilimumab 08.01.05 Formulary NICE TA357: Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab
Ipilimumab 08.01.05 Formulary NICE TA400: Nivolumab in combination with ipilimumab for treating advanced melanoma
Ipilimumab 08.01.05 Formulary NICE TA780: Nivolumab with ipilimumab for untreated advanced renal cell carcinoma
Isatuximab 08.01.05 Formulary NICE TA658: Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma
Ivabradine 02.06.03 Formulary NICE TA267: Ivabradine for treating chronic heart failure
Ivabradine 02.06.03 Formulary NICE CG126: Guidance on Stable Angina (2011)
Ixazomib 08.01.05 Formulary NICE TA870: Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma
Ixekizumab 10.01.03 Formulary NICE TA718: Ixekizumab for treating axial spondyloarthritis
Ixekizumab 10.01.03 Formulary NICE TA537: Ixekizumab for treating active psoriatic arthritis after inadequate response to DMARDs
Ixekizumab 13.05.03 Formulary NICE TA442 Ixekizumab for treating moderate to severe plaque psoriasis
Lamivudine 05.03.03.01 Formulary NICE CG165: Chronic Hepatitis B
Lanadelumab 03.04.03 Formulary NICE TA606: Lanadelumab for preventing recurrent attacks of hereditary angioedema
Lapatinib 08.01.05 Formulary NICE TA257: in combination with an aromatase inhibitor for HER2 positive metastatic breast cancer
Larotrectinib 08.01.05 Formulary NICE TA630: Larotrectinib for treating NTRK fusion-positive solid tumours
Lenalidomide 08.02.04 Formulary NICE TA322: Lenalidomide for treating myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality
Lenalidomide 08.02.04 Formulary NICE TA587: Lenalidomide plus dexamethasone for previously untreated multiple myeloma
Lenalidomide 08.02.04 Formulary NICE TA586: Lenalidomide plus dexamethasone for multiple myeloma after 1 treatment with bortezomib
Lenalidomide 08.02.04 Formulary NICE TA680: Lenalidomide maintenance treatment after an autologous stem cell transplant for newly diagnosed multiple myeloma
Lenalidomide 08.02.04 Formulary NICE TA171: Lenalidomide for the treatment of multiple myeloma in people who have received at least 2 prior therapies
Lenalidomide 08.02.04 Formulary NICE TA27: Lenalidomide with rituximab for previously treated follicular lymphoma
Lenvatinib 08.01.05 Formulary NICE TA 551: Lenvatinib for untreated advanced hepatocellular carcinoma
Lenvatinib 08.01.05 Formulary NICE TA498: Lenvatinib with everolimus for previously treated advanced renal cell carcinoma
Lenvatinib 08.01.05 Formulary NICE TA 535: Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine
Letermovir 05.03.02.02 Formulary NICE TA591: Letermovir for preventing cytomegalovirus disease after a stem cell transplant
Liraglutide 04.05.01 Formulary NICE TA664: Liraglutide for managing overweight and obesity
Liraglutide 06.01.02.03 Formulary NICE NG28: Type 2 diabetes in adults: management
Liraglutide 06.01.02.03 Formulary NICE TA664: Liraglutide for managing overweight and obesity
Liraglutide 06.01.02.03 Formulary NICE NG18: Diabetes (type 1 and type 2) in children and young people: diagnosis and management
Lorlatinib 08.01.05 Formulary NICE TA628: Lorlatinib for previously treated ALK-positive advanced non-small-cell lung cancer
Lubiprostone 01.06.07 Non Formulary NICE TA318: Lubiprostone for treating chronic idiopathic constipation
Lumacaftor and Ivacaftor 03.07 Formulary NICE TA398: Lumacaftor–ivacaftor for treating cystic fibrosis homozygous for the F508del mutation
Lusutrombopag 09.01.04 Formulary NICE TA617: Lusutrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure
Lutetium (177Lu) 08.01.05 Formulary NICE TA539: Lutetium (177Lu) oxodotreotide for treating unresectable or metastatic neuroendocrine tumours
Lutetium (177Lu) 08.01.05 Formulary NICE TA930: Lutetium-177 vipivotide tetraxetan for treating PSMA-positive hormone-relapsed metastatic prostate cancer after 2 or more treatments
Mannitol inhalation 03.07 Formulary NICE TA266: Cystic fibrosis - mannitol dry powder for inhalation
Maribavir 05.03.02.02 Formulary NICE TA860: Maribavir for treating refractory cytomegalovirus infection after transplant
Mavacamten 02.16 Formulary NICE TA913: Mavacamten for treating symptomatic obstructive hypertrophic cardiomyopathy
Melphalan 08.01.01 Formulary NICE TA822: Melphalan for haematological diseases before allogeneic haematopoietic stem cell transplant (terminated appraisal)
Memantine 04.11 Formulary NICE TA217: Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer’s disease
Mepolizumab 03.04.02 Formulary NICE TA671: Mepolizumab for treating severe eosinophilic asthma
Methylprednisolone sodium succinate 40mg, 125mg, 500mg & 1000mg 06.03.02 Formulary NICE NG220: Multiple sclerosis in adults: management
Metreleptin 06.08 Formulary NICE HST14: Metreleptin for treating lipodystrophy
Mexiletine 10.02 Formulary NICE TA748: Mexiletine for treating the symptoms of myotonia in non-dystrophic myotonic disorders
Midostaurin 08.01.05 Formulary NICE TA728: Midostaurin for treating advanced systemic mastocytosis
Midostaurin 08.01.05 Formulary NICE TA523 Midostaurin for untreated acute myeloid leukaemia
Mifamurtide 08.02.04 Formulary NICE TA235: Osteosarcoma - mifamurtide: guidance
Migalastat 09.08.01 Formulary Highly specialised technologies guidance HST4: Migalastat for treating Fabry disease
Mirabegron 07.04.02 Formulary NICE TA290: Mirabegron for overactive bladder
Mobocertinib 08.01.05 Formulary NICE TA855: Mobocertinib for treating EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy
Mogamulizumab 08.01.05 Formulary NICE TA754: Mogamulizumab for previously treated mycosis fungoides and Sézary syndrome
Mosunetuzumab 08.01.05 Non Formulary NICE TA892: Mosunetuzumab for treating relapsed or refractory follicular lymphoma
Mycophenolate Mofetil 08.02.01 Formulary NICE TA481: Immunosuppressive therapy for kidney transplant in adults
Naftidrofuryl 02.06.04 Formulary NICE TA223: Intermittent claudication drugs
Naftidrofuryl 02.06.04 Formulary NICE CG147: Lower limb peripheral arterial disease management
Naldemedine 01.06.06 Formulary NICE TA651 - Naldemedine for treating opioid-induced constipation
Nalmefene 04.10.01 Formulary NICE TA325: Nalmefene for reducing alcohol consumption in people with alcohol dependence
Naloxegol 01.06.06 Formulary NICE TA345: Naloxegol for treating opioid‑induced constipation
Naltrexone 50 mg tablets 04.10.03 Formulary NICE TA115: Drug misuse - naltrexone
Natalizumab 08.02.04 Formulary NICE TA127: Natalizumab for the treatment of adults with highly active relapsing–remitting multiple sclerosis
Necitumumab 08.01.05 Formulary NICE TA411: Necitumumab for untreated advanced or metastatic squamous non-small-cell lung cancer
Neratinib 08.01.05 Formulary NICE TA612: Neratinib for extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer after adjuvant trastuzumab
Nilotinib 08.01.05 Formulary NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
Nilotinib 08.01.05 Formulary NICE TA425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
Nintedanib 03.11 Formulary NICE TA379:Nintedanib for treating idiopathic pulmonary fibrosis
Nintedanib 03.11 Formulary NICE TA747: Nintedanib for treating progressive fibrosing interstitial lung diseases
Nintedanib 08.01.05 Formulary NICE TA747 Nintedanib for treating progressive fibrosing interstitial lung diseases
Nintedanib 08.01.05 Formulary NICE TA379: Nintedanib for treating idiopathic pulmonary fibrosis
Nintedanib 08.01.05 Formulary NICE TA347: Recurrent non-small-cell lung cancer
Nintedanib 08.01.05 Formulary NICE TA864: Nintedanib for treating idiopathic pulmonary fibrosis when forced vital capacity is above 80% predicted
Niraparib 08.01.05 Formulary NICE TA784: Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer
Niraparib 08.01.05 Formulary NICE TA673: Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy
Nirmatrelvir and Ritonavir 05.03.06 Formulary NICE TA878: Casirivimab plus imdevimab, nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19
Nivolumab 08.01.05 Formulary NICE TA400: Nivolumab in combination with ipilimumab for treating advanced melanoma
Nivolumab 08.01.05 Formulary NICE TA462 Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma
Nivolumab 08.01.05 Formulary NICE TA417: Nivolumab for previously treated advanced renal cell carcinoma
Nivolumab 08.01.05 Formulary NICE TA384: Nivolumab for treating advanced (unresectable or metastatic) melanoma
Nivolumab 08.01.05 Formulary NICE TA818: Nivolumab with ipilimumab for untreated unresectable malignant pleural mesothelioma
Nivolumab 08.01.05 Formulary NICE TA713: Nivolumab for advanced non-squamous non-small-cell lung cancer after chemotherapy
Nivolumab 08.01.05 Formulary NICE TA865: Nivolumab with fluoropyrimidine- and platinum-based chemotherapy for untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma
Nivolumab 08.01.05 Formulary NICE TA876: Nivolumab with chemotherapy for neoadjuvant treatment of resectable non-small-cell lung cancer
Nivolumab 08.01.05 Formulary NICE TA530: Nivolumab for treating locally advanced unresectable or metastatic urothelial cancer after platinum-containing chemotherapy
Nivolumab 08.01.05 Formulary NICE TA724: Nivolumab with ipilimumab and chemotherapy for untreated metastatic non-small- cell lung cancer
Nivolumab 08.01.05 Formulary NICE TA655: Nivolumab for advanced squamous non-small-cell lung cancer after chemotherapy
Nivolumab 08.01.05 Formulary NICE TA684: Nivolumab for adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease
Nivolumab 08.01.05 Formulary NICE TA716: Nivolumab with ipilimumab for previously treated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency
Nivolumab 08.01.05 Formulary NICE TA707: Nivolumab for previously treated unresectable advanced or recurrent oesophageal cancer
Nivolumab 08.01.05 Formulary NICE TA817: Nivolumab for adjuvant treatment of invasive urothelial cancer at high risk of recurrence
Nivolumab 08.01.05 Formulary NICE TA746: Nivolumab for adjuvant treatment of resected oesophageal or gastro-oesophageal junction cancer
Nivolumab 08.01.05 Formulary NICE TA780: Nivolumab with ipilimumab for untreated advanced renal cell carcinoma
Nivolumab 08.01.05 Formulary NICE TA736: Nivolumab for treating recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy
Nusinersen 10.02 Formulary NICE TA588: Nusinersen for treating spinal muscular atrophy
Obeticholic acid 01.09.01 Formulary NICE TA443 Obeticholic acid for treating primary biliary cholangitis
Obinutuzumab 08.02.03 Formulary NICE TA343: Obinutuzumab with chlorambucil for CLL
Obinutuzumab 08.02.03 Formulary NICE TA629: Obinutuzumab with bendamustine for treating follicular lymphoma after rituximab
Ocrelizumab 08.02.03 Formulary NICE TA 533: Ocrelizumab for treating relapsing–remitting multiple sclerosis
Ocrelizumab 08.02.03 Formulary NICE TA585: Ocrelizumab for treating primary progressive multiple sclerosis
Ocriplasmin 11.08.02 Formulary NICE TA 297 Ocriplasmin for treating vitreomacular traction
Odevixibat 01.09.01 Formulary NICE HST17: Odevixibat for treating progressive familial intrahepatic cholestasis
Ofatumumab 08.02.03 Formulary NICE TA699: Ofatumumab for treating relapsing multiple sclerosis
Olaparib 08.01.05 Formulary NICE TA908: Olaparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube or peritoneal cancer after 2 or more courses of platinum-based chemotherapy
Olaparib 08.01.05 Formulary NICE TA886: Olaparib for adjuvant treatment of BRCA mutation-positive HER2-negative high-risk early breast cancer after chemotherapy
Olaparib 08.01.05 Formulary NICE TA887: Olaparib for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer
Omalizumab 03.04.02 Formulary NICE TA339: Omalizumab for previously treated chronic spontaneous urticaria
Omalizumab 03.04.02 Formulary NICE TA278: Omalizumab for treating allergic asthma
Omalizumab 03.04.02 Formulary NICE TA678: Omalizumab for treating chronic rhinosinusitis with nasal polyps (terminated appraisal)
Ombitasvir & paritaprevir & ritonavir 05.03.03.02 Non Formulary NICE TA365: Ombitasvir–paritaprevir–ritonavir with or without dasabuvir for treating chronic hepatitis C
Onasemnogene abeparvovec 19 Formulary NICE HST15: Onasemnogene abeparvovec for treating spinal muscular atrophy
Oseltamivir 05.03.04 Formulary NICE TA168: Amantadine, oseltamivir and zanamivir for the treatment of influenza
Oseltamivir 05.03.04 Formulary NICE TA158: Oseltamivir, amantadine (review) and zanamivir for the prophylaxis of influenza
Osimertinib 08.02.04 Formulary NICE TA654: Osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer
Osimertinib 08.02.04 Formulary NICE TA761 Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection
Osimertinib 08.02.04 Formulary NICE TA 653: Osimertinib for treating EGFR T790M mutation-positive advanced non-small-cell lung cancer
Oxaliplatin 08.01.05 Formulary NICE TA100: Capecitabine and oxaliplatin in the adjuvant treatment of stage III (Dukes’ C) colon cancer
Ozanimod 01.05.03 Formulary NICE TA 828: Ozanimod for treating moderately to severely active ulcerative colitis
Paclitaxel 08.01.05 Formulary NICE TA55: Guidance on the use of paclitaxel in the treatment of ovarian cancer
Paclitaxel 08.01.05 Formulary NICE TA389 - Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
Paclitaxel - Albumin Bound Formulation 08.01.05 Formulary NICE TA476 Paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer
Palbociclib 08.03.04.01 Formulary NICE TA495: Palbociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer
Palbociclib 08.03.04.01 Formulary NICE TA836: Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy
Panitumumab 08.01.05 Formulary NICE TA439 Cetuximab and panitumumab for previously untreated metastatic colorectal cancer
Panobinostat 08.01.05 Formulary NICE TA380: Panobinostat for treating multiple myeloma after at least 2 previous treatments
Patiromer calcium (as Patiromer sorbitex calcium) 09.02.01.01 Formulary NICE TA623: Patiromer for treating hyperkalaemia
Patisiran 04.12 Formulary NICE Highly specialised technologies 10: Patisiran for treating hereditary transthyretin amyloidosis
Pazopanib 08.01.05 Formulary NICE TA215: Pazopanib in renal cell cancer
Peanut Allergy 03.04.02 Formulary NICE TA769: Palforzia for treating peanut allergy in children and young people
Pegaspargase 3750iu vial 08.01 Formulary NICE TA408: Pegaspargase for treating acute lymphoblastic leukaemia
Pegcetacoplan 09.01.03 Formulary NICE TA778: Pegcetacoplan for treating paroxysmal nocturnal haemoglobinuria
Peginterferon Alfa 08.02.04 Formulary NICE TA96: Hepatitis B - peginterferon alfa
Peginterferon Alfa 08.02.04 Formulary NICE TA300: Hepatitis C - peginterferon alfa
Peginterferon Alfa 08.02.04 Formulary NICE TA200: Hepatitis C - peginterferon alfa & ribavirin
Peginterferon Alfa 08.02.04 Formulary NICE TA75: Hepatitis C - pegylated interferons, ribavirin & alfa interferon
Peginterferon Alfa 08.02.04 Formulary NICE TA106: Hepatitis C - peginterferon alfa & ribavirin
Peginterferon Alfa 08.02.04 Formulary NICE CG165: Hepatitis B (chronic): diagnosis and management
Peginterferon Beta-1a 08.02.04 Formulary NICE TA624: Peginterferon beta-1a for treating relapsing–remitting multiple sclerosis
Pegloticase 20 Non Formulary NICE TA291: Pegloticase not recommended for severe chronic gout
Pegunigalsidase alfa 09.08.01 Formulary NICE TA915: Pegunigalsidase alfa for treating Fabry’s disease
Pembrolizumab 08.01.05 Formulary NICE TA683: Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer
Pembrolizumab 08.01.05 Formulary NICE TA885: Pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer
Pembrolizumab 08.01.05 Formulary NICE TA837: Pembrolizumab for adjuvant treatment of resected stage 2B or 2C melanoma
Pembrolizumab 08.01.05 Formulary NICE TA737: Pembrolizumab with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced oesophageal and gastro-oesophageal junction cancer
Pembrolizumab 08.01.05 Formulary NICE TA801: Pembrolizumab plus chemotherapy for untreated, triple-negative, locally recurrent unresectable or metastatic breast cancer
Pembrolizumab 08.01.05 Formulary NICE TA830: Pembrolizumab for adjuvant treatment of renal cell carcinoma
Pembrolizumab 08.01.05 Formulary NICE TA709: Pembrolizumab for untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency
Pembrolizumab 08.01.05 Formulary NICE TA766: Pembrolizumab for adjuvant treatment of completely resected stage 3 melanoma
Pembrolizumab 08.01.05 Formulary NICE TA770: Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer
Pembrolizumab 08.01.05 Formulary NICE TA772: Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma after stem cell transplant or at least 2 previous therapies
Pembrolizumab 08.01.05 Formulary NICE TA939: Pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer
Pembrolizumab 08.01.05 Formulary NICE TA914: Pembrolizumab for previously treated endometrial, biliary, colorectal, gastric or small intestine cancer with high microsatellite instability or mismatch repair deficiency
Pembrolizumab 08.01.05 Formulary NICE TA366: Pembrolizumab for advanced melanoma not previously treated with ipilimumab
Pembrolizumab 08.01.05 Formulary NICE TA904: Pembrolizumab with lenvatinib for previously treated advanced or recurrent endometrial cancer
Pembrolizumab 08.01.05 Formulary NICE TA692: Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy
Pembrolizumab 08.01.05 Formulary NICE TA531: Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer
Pembrolizumab 08.01.05 Formulary NICE TA661: Pembrolizumab for untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma
Pembrolizumab 08.01.05 Formulary NICE TA428: Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy
Pembrolizumab 08.01.05 Formulary NICE TA357: Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab
Pemetrexed 08.01.03 Formulary NICE TA402: Pemetrexed maintenance treatment for non-squamous non-small-cell lung cancer after pemetrexed and cisplatin
Pemetrexed 08.01.03 Formulary NICE TA124: Pemetrexed for the treatment of non-small-cell lung cancer
Pemetrexed 08.01.03 Formulary NICE TA181: Pemetrexed for the first-line treatment of non-small-cell lung cancer
Pemetrexed 08.01.03 Formulary NICE TA190: Pemetrexed for the maintenance treatment of non-small-cell lung cancer
Pemetrexed 08.01.03 Formulary NICE TA135: Pemetrexed for the treatment of malignant pleural mesothelioma
Pemigatinib 08.01.05 Formulary NICE TA722: Pemigatinib for treating relapsed or refractory advanced cholangiocarcinoma with FGFR2 fusion or rearrangement
Pentosan Polysulphate Sodium 07.04.03 Formulary NICE TA610: Pentosan polysulfate sodium for treating bladder pain syndrome
Perampanel 04.08.01 Non Formulary NICE CG137: The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care
Pertuzumab 08.01.05 Formulary NICE TA424: Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer
Pertuzumab 08.01.05 Formulary NICE TA569: Pertuzumab for adjuvant treatment of HER2-positive early stage breast cancer
Pertuzumab 08.01.05 Formulary NICE TA509: Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer
Pimecrolimus cream 13.05.03 Formulary NICE TA82: Pimecrolimus and tacrolimus for atopic dermatitis (eczema)
Pirfenidone 03.11 Formulary NICE TA504: Idiopathic pulmonary fibrosis - pirfenidone
Pitolisant 04.04 Formulary NICE TA776: Pitolisant hydrochloride for treating excessive daytime sleepiness caused by obstructive sleep apnoea
Pixantrone 08.01.02 Formulary NICE TA306: Pixantrone monotherapy
Polatuzumab vedotin 08.01.05 Formulary NICE TA649: Polatuzumab vedotin with rituximab and bendamustine for treating relapsed or refractory diffuse large B-cell lymphoma
Polatuzumab vedotin 08.01.05 Formulary NICE TA874: Polatuzumab vedotin in combination for untreated diffuse large B-cell lymphoma
Pomalidomide 08.01.05 Formulary NICE TA427: Pomalidomide for multiple myeloma previously treated with lenalidomide and bortezomib
Pomalidomide 08.02.04 Formulary NICE TA427: Pomalidomide for multiple myeloma previously treated with lenalidomide and bortezomib
Ponatinib 08.01.05 Formulary NICE TA451 Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia
Ponesimod 08.02.04 Formulary NICE TA767: Ponesimod for treating relapsing–remitting multiple sclerosis
Prasugrel 02.09 Formulary NICE TA317 (replaces TA182): Acute coronary syndrome - prasugrel
Prucalopride 01.06.07 Formulary NICE TA211: Constipation (women) - prucalopride
Radium-223 dichloride 08.03.04.02 Formulary NICE TA412: Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases
Raloxifene Hydrochloride 06.04.01.01 Formulary NICE TA161: Raloxifene and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women
Raloxifene Hydrochloride 06.04.01.01 Formulary NICE TA160: Raloxifene for the primary prevention of osteoporotic fragility fractures in postmenopausal women (Not Approved)
Ramucirumab 08.01.05 Formulary NICE TA403: Ramucirumab for previously treated locally advanced or metastatic non-small-cell lung cancer
Ramucirumab 08.01.05 Formulary NICE TA378: Ramucirumab for treating advanced gastric cancer or gastro–oesophageal junction adenocarcinoma previously treated with chemotherapy
Ranibizumab 10mg/1ml injection 11.08.02 Formulary NICE TA 274 Ranibizumab for treating diabetic macular oedema
Ranibizumab 10mg/1ml injection 11.08.02 Formulary NICE TA 298 Ranibizumab for treating choroidal neovascularisation associated with pathological myopia
Ranibizumab 10mg/1ml injection 11.08.02 Formulary NICE TA 283 Ranibizumab for treating visual impairment caused by macular oedema secondary to retinal vein occlusion
Ranibizumab 10mg/1ml injection 11.08.02 Formulary NICE TA 155 Ranibizumab and pegaptanib for the treatment of age-related macular degeneration
Ranolazine 02.06.03 Formulary NICE CG126: Guidance on Stable Angina (2011)
Ravulizumab 09.01.03 Formulary NICE TA698: Ravulizumab for treating paroxysmal nocturnal haemoglobinuria
Ravulizumab 09.01.03 Formulary NICE TA710: Ravulizumab for treating atypical haemolytic uraemic syndrome
Regorafenib 08.01.05 Formulary NICE TA866: Regorafenib for previously treated metastatic colorectal cancer
Regorafenib 08.01.05 Formulary NICE TA555: Regorafenib for previously treated advanced hepatocellular carcinoma
Regorafenib 08.01.05 Formulary NICE TA 488: Regorafenib for previously treated unresectable or metastatic gastrointestinal stromal tumours
Relugolix–estradiol–norethisterone acetate 06.07.02 Formulary NICE TA832: Relugolix–estradiol–norethisterone acetate for treating moderate to severe symptoms of uterine fibroids
Reslizumab 03.04.02 Formulary NICE TA479 Reslizumab for treating severe eosinophilic asthma
Retigabine 04.08.01 Formulary NICE TA232: Retigabine for the adjunctive treatment of adults with partial onset seizures in epilepsy with and without secondary generalisation
Ribavirin 05.03.03.02 Formulary NICE TA106: Hepatitis C - peginterferon alfa and ribavirin
Ribavirin 05.03.03.02 Formulary NICE TA75: Hepatitis C - pegylated interferons, ribavirin and alfa interferon
Ribavirin 05.03.03.02 Formulary NICE TA200: Hepatitis C - peginterferon alfa and ribavirin
Ribociclib 08.03.04.01 Formulary NICE TA687: Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy
Ribociclib 08.03.04.01 Formulary NICE TA496: Ribociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer
Rifaximin 05.01.07 Formulary TA337: Rifaximin for preventing episodes of overt hepatic encephalopathy
Riluzole 04.09.03 Formulary NICE TA20: Motor neurone disease - riluzole
Rimegepant 04.07.04.02 Formulary NICE TA919: Rimegepant for treating migraine
Rimegepant 04.07.04.02 Formulary NICE TA906: Rimegepant for preventing migraine
Ripretinib 08.01.05 Non Formulary NICE TA881: Ripretinib for treating advanced gastrointestinal stromal tumour after 3 or more treatments
Risankizumab 01.05.03 Formulary NICE TA888: Risankizumab for previously treated moderately to severely active Crohn’s disease
Risankizumab 13.05.03 Formulary NICE TA596: Risankizumab for treating moderate to severe plaque psoriasis
Risdiplam 10.02 Formulary NICE TA755: Risdiplam for treating spinal muscular atrophy
Risedronate 06.06.02 Formulary NICE TA464 Bisphosphonates for treating osteoporosis
Rituximab 08.02.03 Formulary NICE TA137: Rituximab for the treatment of relapsed or refractory stage III or IV follicular non- Hodgkin’s lymphoma
Rituximab 08.02.03 Formulary NICE TA174: Rituximab for the first-line treatment of chronic lymphocytic leukaemia
Rituximab 08.02.03 Formulary NICE TA193: Rituximab for the treatment of relapsed or refractory chronic lymphocytic leukaemia
Rituximab 08.02.03 Formulary NICE TA226: Rituximab for the first-line maintenance treatment of follicular non-Hodgkin’s lymphoma
Rituximab 08.02.03 Formulary NICE TA243: Rituximab for the first-line treatment of stage III-IV follicular lymphoma
Rituximab 10.01.03 Formulary NICE TA195: Rheumatoid arthritis - after failure of a TNF inhibitor
Rivaroxaban 02.08.02 Formulary NICE TA170: Rivaroxaban for the prevention of venous thromboembolism after total hip or total knee replacement in adults
Rivaroxaban 02.08.02 Formulary NICE TA256: Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation
Rivaroxaban 02.08.02 Formulary NICE TA261: Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism
Rivaroxaban 02.08.02 Formulary NICE TA335: Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome
Rivaroxaban 02.08.02 Formulary NICE TA287: Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism
Rivaroxaban 02.08.02 Formulary NICE TA607: Rivaroxaban for preventing atherothrombotic events in people with coronary or peripheral artery disease
Rivastigmine 04.11 Formulary NICE TA217: Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer’s disease
Roflumilast 03.03.03 Formulary NICE TA461: Roflumilast for treating chronic obstructive pulmonary disease
Romiplostim 09.01.04 Formulary NICE TA221: Thrombocytopenic purpura - romiplostim
Romosozumab 06.06.02 Formulary NICE TA791: Romosozumab for treating severe osteoporosis
Roxadustat 09.01.03 Formulary NICE TA807: Roxadustat for treating symptomatic anaemia in chronic kidney disease
Ruxolitinib 08.01.05 Formulary NICE TA921: Ruxolitinib for treating polycythaemia vera
Ruxolitinib 08.01.05 Formulary NICE TA386: Ruxolitinib for treating disease-related splenomegaly or symptoms in adults with myelofibrosis
Sacituzumab govitecan 08.01.05 Formulary NICE TA819: Sacituzumab govitecan for treating unresectable triple-negative advanced breast cancer after 2 or more therapies
Sacubitril & valsartan 02.05.05.02 Formulary NICE TA388: Sacubitril valsartan for heart failure (updated 16/7/16 to include adoption resources)
Sapropterin dihydrochloride 09.04.01 Formulary NICE TA729: Sapropterin for treating hyperphenylalaninaemia in phenylketonuria
Sarilumab 10.01.03 Formulary NICE TA485: Sarilumab for moderate to severe rheumatoid arthritis
Secukinumab 10.01.03 Formulary NICE TA407: Secukinumab for active ankylosing spondylitis after treatment with non-steroidal anti-inflammatory drugs or TNF-alpha inhibitors
Secukinumab 10.01.03 Formulary NICE TA445: Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs
Secukinumab 10.01.03 Formulary NICE TA719: Secukinumab for treating non-radiographic axial spondyloarthritis
Secukinumab 13.05.03 Formulary NICE TA350: Secukinumab for treating moderate to severe plaque psoriasis
Secukinumab 13.05.03 Formulary NICE TA734: Secukinumab for treating moderate to severe plaque psoriasis in children and young people
Secukinumab 13.05.03 Formulary NICE TA935: Secukinumab for treating moderate to severe hidradenitis suppurativa
Selpercatinib 08.01.05 Formulary NICE TA911: Selpercatinib for untreated RET fusion-positive advanced non-small-cell lung cancer
Selpercatinib 08.01.05 Formulary NICE TA760: Selpercatinib for previously treated RET fusion-positive advanced non-small-cell lung cancer
Selpercatinib 08.01.05 Formulary NICE TA742: Selpercatinib for treating advanced thyroid cancer with RET alterations
Selumetinib 08.01.05 Formulary NICE HST20 Selumetinib for treating symptomatic and inoperable plexiform neurofibromas associated with type 1 neurofibromatosis in children aged 3 and over
Selumetinib 08.01.05 Formulary NICE HST20: Selumetinib for treating symptomatic and inoperable plexiform neurofibromas associated with type 1 neurofibromatosis in children aged 3 and over
Semaglutide 06.01.02.03 Formulary NICE TA875: Semaglutide for managing overweight and obesity
Semaglutide 06.01.02.03 Formulary NICE TA875: Semaglutide for managing overweight and obesity
Setmelanotide 06.07 Formulary NICE HST21: Setmelanotide for treating obesity caused by LEPR or POMC deficiency
Simeprevir 05.03.03.02 Non Formulary NICE TA331: Simeprevir with peginterferon alfa & ribavirin for hepatitis C
Siponimod 08.02.04 Formulary NICE TA656: Siponimod for treating secondary progressive multiple sclerosis
Sipuleucel- T 20 Non Formulary NICE TA322: Sipuleucel-T for prostate cancer
Sodium zirconium cyclosilicate 09.02.01.01 Formulary NICE TA599: Sodium zirconium cyclosilicate for treating hyperkalaemia
Sofosbuvir 05.03.03.02 Formulary NICE TA330: Sofosbuvir for treating chronic hepatitis C
Sofosbuvir & Ledipasvir 05.03.03.02 Formulary NICE TAG63: Ledipasvir–sofosbuvir for treating chronic hepatitis C
Sofosbuvir & velpatasvir 05.03.03.02 Formulary NICE TA430: Sofosbuvir–velpatasvir for treating chronic hepatitis C
Sofosbuvir, Velpatasvir & Voxilaprevir 05.03.03.02 Formulary NICE TA507: Sofosbuvir–velpatasvir–voxilaprevir for treating chronic hepatitis C
Solriamfetol 04.04 Formulary NICE TA758: Solriamfetol for treating excessive daytime sleepiness caused by narcolepsy
Solriamfetol 04.04 Formulary NICE TA777: Solriamfetol for treating excessive daytime sleepiness caused by obstructive sleep apnoea (Not Recommended)
Somatrogon 06.05.01 Formulary NICE TA863: Somatrogon for treating growth disturbance in children and young people aged 3 years and over
Somatropin - adults 06.05.01 Formulary NICE TA64: Human growth hormone (somatropin) in adults with growth hormone deficiency
Somatropin (children) 06.05.01 Formulary NICE TA188: Human growth hormone (somatropin) for the treatment of growth failure in children
Sorafenib 08.01.05 Formulary NICE TA 535: Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine
Sorafenib 08.01.05 Formulary NICE TA474 Sorafenib for treating advanced hepatocellular carcinoma
Sotagliflozin 06.01.02.03 Formulary NICE TA622: Sotagliflozin with insulin for treating type 1 diabetes
Sotrovimab 05.03.06 Formulary NICE TA878: Casirivimab plus imdevimab, nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19
Sunitinib 08.01.05 Formulary NICE TA449 Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease
Sunitinib 08.01.05 Formulary NICE TA179: Sunitinib for the treatment of gastrointestinal stromal tumours
Sunitinib 08.01.05 Formulary NICE TA169: Sunitinib for the first-line treatment of advanced and/or metastatic renal cell carcinoma
Tacrolimus 08.02.02 Formulary NICE TA482: Immunosuppressive therapy for kidney transplant in children and young people
Tacrolimus 08.02.02 Formulary NICE TA481: Immunosuppressive therapy for kidney transplant in adults
Tacrolimus ointment 13.05.03 Formulary NICE TA82: Pimecrolimus and tacrolimus for atopic dermatitis (eczema)
Tafasitamab 08.01.05 Non Formulary NICE TA883: Tafasitamab with lenalidomide for treating relapsed or refractory diffuse large B-cell lymphoma
Talimogene laherparepvec 08.01.05 Formulary NICE TA410: Talimogene laherparepvec for treating unresectable metastatic melanoma
Teduglutide 01.04.02 Formulary NICE TA804: Teduglutide for treating short bowel syndrome
Tegafur with Uracil 08.01.03 Formulary NICE TA61: Guidance on the use of capecitabine and tegafur with uracil for metastatic colorectal cancer
Telaprevir 05.03.03.02 Non Formulary NICE TA252: Telaprevir in hepatitis C
Temozolomide 08.01.05 Formulary NICE TA23: Guidance on the use of temozolomide for the treatment of recurrent malignant glioma (brain cancer)
Temozolomide 08.01.05 Formulary NICE TA121: Glioma (newly diagnosed and high grade)
Tenofovir Disproxil 05.03.03.01 Formulary NICE TA173: Hepatitis B (chronic) - tenofovir disoproxil
Tenofovir Disproxil 05.03.03.01 Formulary NICE CG165: Hepatitis B (incorporates TA153)
Tepotinib 08.02 Formulary NICE TA789: Tepotinib for treating advanced non-small-cell lung cancer with MET gene alterations
Teriflunomide 08.02.04 Formulary NICE TA303: Teriflunomide for treating relapsing–remitting multiple sclerosis
Teriparatide 250microgram in 1ml prefilled pen 06.06.01 Formulary NICE TA160: Raloxifene for the primary prevention of osteoporotic fragility fractures in postmenopausal women
Teriparatide 250microgram in 1ml prefilled pen 06.06.01 Formulary NICE TA161: Raloxifene and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women
Teriparatide 250microgram in 1ml prefilled pen 06.06.01 Formulary NICE TA160: Raloxifene for the primary prevention of osteoporotic fragility fractures in postmenopausal women
Teriparatide 250microgram in 1ml prefilled pen 06.06.01 Formulary NICE TA161: Raloxifene and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women
Testosterone (1.62%) 06.04.02 Formulary NICE NG23: Menopause: diagnosis and management
Tezepelumab 03.04.02 Formulary NICE TA880: Tezepelumab for treating severe asthma
Thalidomide 08.02.04 Formulary NICE TA228: Bortezomib and thalidomide for the first‑line treatment of multiple myeloma
Thiamine 09.06.02 Formulary NICE CG100: Management of alcohol-related physical complications
Thiamine 09.06.02 Formulary NICE CG115: Alcohol dependence - diagnosis, assessment and management
Ticagrelor 02.09 Formulary NICE TA236: Ticagrelor for the treatment of acute coronary syndromes
Ticagrelor 02.09 Formulary NICE TA420: Ticagrelor for preventing atherothrombotic events after myocardial infarction
Tildrakizumab 13.05.03 Formulary NICE TA575: Tildrakizumab for treating moderate to severe plaque psoriasis
Tinzaparin 02.08.01 Formulary Venous thromboembolic diseases: diagnosis, management and thrombophilia testing
Tinzaparin 02.08.01 Formulary Venous thromboembolism in over 16s: reducing the risk of hospital-acquired deep vein thrombosis or pulmonary embolism
Tirzepatide 06.01.02.03 Formulary NICE TA924: Tirzepatide for treating type 2 diabetes
Tisagenlecleucel 08.01.05 Non Formulary NICE TA933: Tisagenlecleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies (terminated appraisal)
Tisagenlecleucel 08.01.05 Formulary NICE TA554: Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up to 25 years
Tivozanib 08.01.05 Formulary NICE TA512: Tivozanib for treating advanced renal cell carcinoma
Tobramycin 05.01.04 Formulary TA276:Colistimethate sodium and tobramycin dry powders for inhalation for treating pseudomonas lung infection in cystic fibrosis
Tobramycin inhaler 05.01.04 Non Formulary NICE TA276: Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin
Tocilizumab 10.01.03 Formulary NICE TA247: Tocilizumab for the treatment of rheumatoid arthritis
Tocilizumab 10.01.03 Formulary NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
Tocilizumab 10.01.03 Formulary NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis
Tocilizumab 10.01.03 Formulary NICE TA518: Tocilizumab for treating giant cell arteritis
Tofacitinib 10.01.03 Formulary NICE TA547: Tofacitinib for moderately to severely active ulcerative colitis
Tofacitinib 10.01.03 Formulary NICE TA543: Tofacitinib for treating active psoriatic arthritis after inadequate response to DMARDs
Tofacitinib 10.01.03 Formulary NICE TA480: Tofacitinib for moderate to severe rheumatoid arthritis Technology appraisal guidance
Tofacitinib 10.01.03 Formulary NICE TA735: Tofacitinib for treating juvenile idiopathic arthritis
Tofacitinib 10.01.03 Formulary NICE TA920: Tofacitinib for treating active ankylosing spondylitis
Tofacitinib 01.05.03 Formulary NICE TA547: Tofacitinib for moderately to severely active ulcerative colitis
Tolvaptan 06.05.02 Formulary NICE TA358: Autosomal dominant polycystic kidney disease - tolvaptan
Tolvaptan 06.05.02 Non Formulary NICE TA358: Autosomal dominant polycystic kidney disease - tolvaptan
Topotecan 08.01.05 Formulary NICE TA389 - Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
Topotecan 08.01.05 Formulary NICE TA183: Topotecan for the treatment of recurrent and stage IVB cervical cancer
Topotecan 08.01.05 Formulary NICE TA184: Topotecan for the treatment of relapsed small-cell lung cancer
Trabectedin 08.01.05 Formulary NICE TA185: Soft tissue sarcoma - trabectedin
Trabectedin 08.01.05 Formulary NICE TA389 - Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
Tralokinumab 13.05.03 Formulary NICE TA814: Abrocitinib, tralokinumab or upadacitinib for treating moderate to severe atopic dermatitis
Trametinib 08.01.05 Formulary NICE TA396: Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma
Trametinib 08.01.05 Formulary NICE TA544: Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma
Trastuzumab 08.01.05 Formulary NICE TA257: in combination with an aromatase inhibitor for HER2 positive metastatic breast cancer
Trastuzumab 08.01.05 Formulary NICE TA34: Breast cancer - trastuzumab
Trastuzumab 08.01.05 Formulary NICE TA208: Gastric cancer (HER2-positive metastatic) - trastuzumab
Trastuzumab 08.01.05 Formulary NICE NG101: Early and locally advanced breast cancer: diagnosis and management
Trastuzumab deruxtecan 08.01.05 Formulary NICE TA704: Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 2 or more anti-HER2 therapies
Trastuzumab deruxtecan 08.01.05 Formulary NICE TA862: HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments
Trastuzumab emtansine 08.01.05 Formulary NICE TA458 Trastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab and a taxane
Trastuzumab emtansine 08.01.05 Formulary NICE TA632: Trastuzumab emtansine for adjuvant treatment of HER2-positive early breast cancer
Treosulfan 08.01.01 Formulary NICE TA640: Treosulfan with fludarabine for malignant disease before allogeneic stem cell transplant
Trifluridine and tipiracil 08.01.03 Formulary NICE TA 405 - Trifluridine–tipiracil for previously treated metastatic colorectal cancer
Trifluridine and tipiracil 08.01.03 Formulary NICE TA852: Trifluridine–tipiracil for treating metastatic gastric cancer or gastro-oesophageal junction adenocarcinoma after 2 or more treatments
Tucatinib 08.01.05 Formulary NICE TA786: Tucatinib with trastuzumab and capecitabine for treating HER2-positive advanced breast cancer after 2 or more anti-HER2 therapies
Upadacitinib 13.05.03 Formulary NICE TA814: Abrocitinib, tralokinumab or upadacitinib for treating moderate to severe atopic dermatitis
Upadacitinib 01.05.03 Formulary NICE TA905: Upadacitinib for previously treated moderately to severely active Crohn’s disease
Upadacitinib 01.05.03 Formulary NICE TA856: Upadacitinib for treating moderately to severely active ulcerative colitis
Upadacitinib 10.01.03 Formulary NICE TA814: Abrocitinib, tralokinumab or upadacitinib for treating moderate to severe atopic dermatitis
Upadacitinib 10.01.03 Formulary NICE TA744: Upadacitinib for treating moderate rheumatoid arthritis
Upadacitinib 10.01.03 Formulary NICE TA861: Upadacitinib for treating active non-radiographic axial spondyloarthritis
Upadacitinib 10.01.03 Formulary NICE TA768: Upadacitinib for treating active psoriatic arthritis after inadequate response to DMARDs
Upadacitinib 10.01.03 Formulary NICE TA665: Upadacitinib for treating severe rheumatoid arthritis
Upadacitinib 10.01.03 Formulary NICE TA829: Upadacitinib for treating active ankylosing spondylitis
Ustekinumab 10.01.03 Formulary NICE TA340: Ustekinumab for treating active psoriatic arthritis (Updated March 2017)
Ustekinumab 01.05.03 Formulary NICE TA456 Ustekinumab for moderately to severely active Crohn’s disease after previous treatment
Ustekinumab 01.05.03 Formulary NICE TA633: Ustekinumab for treating moderately to severely active ulcerative colitis
Ustekinumab 13.05.03 Formulary NICE TA180: Psoriasis - ustekinumab (Updated March 2017)
Ustekinumab 13.05.03 Formulary NICE TA455 Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people
Vaginal Devices 07.04.02 Formulary NICE NG210: Pelvic floor dysfunction: prevention and non-surgical management
Varenicline 04.10.02 Formulary NICE TA123: Varenicline
Vedolizumab 01.05.03 Formulary NICE TA826: Vedolizumab for treating chronic refractory pouchitis after surgery for ulcerative colitis (terminated appraisal)
Vedolizumab 01.05.03 Formulary NICE TA342: Vedolizumab for treating moderately to severely active ulcerative colitis
Vedolizumab 01.05.03 Formulary NICE TA352: Vedolizumab for treating moderately to severely active Crohn’s disease after prior therapy
Velmanase alfa 09.08.01 Formulary NICE HST29: Velmanase alfa for treating alpha-mannosidosis
Vemurafenib 08.01.05 Formulary NICE TA269: Vemurafenib for treating malignant melanoma
Vemurafenib 08.01.05 Formulary NICE TA414: Cobimetinib in combination with vemurafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma
Venetoclax 08.01.05 Formulary NICE TA663 Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia
Venetoclax 08.01.05 Formulary NICE TA765: Venetoclax with azacitidine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable
Venetoclax 08.01.05 Formulary NICE TA787: Venetoclax with low dose cytarabine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable
Venetoclax 08.01.05 Formulary NICE TA796: Venetoclax for treating chronic lymphocytic leukaemia
Venetoclax 08.01.05 Formulary NICE TA561: Venetoclax with rituximab for previously treated chronic lymphocytic leukaemia
Verteporfin 15mg Injection 11.08.02 Formulary NICE NG82: Age-related macular degeneration
Vinflunine 08.01.04 Non Formulary NICE TA272: Urothelial tract carcinoma (transitional cell, advanced, metastatic) - vinflunine
Vitamin B & C injection 09.06.02 Formulary NICE CG115: Alcohol dependence - diagnosis, assessment and management
Vitamin B & C injection 09.06.02 Formulary NICE CG100: Management of alcohol-related physical complications
Voclosporin 08.02.02 Formulary NICE TA882: Voclosporin with mycophenolate mofetil for treating lupus nephritis
Volanesorsen 19 Formulary NICE HST 13: Volanesorsen for treating familial chylomicronaemia syndrome
Vortioxetine 04.03.04 Formulary NICE TA367: Vortioxetine for treating major depressive episodes
Vortioxetine 04.03.03 Non Formulary NICE TA367 - Vortioxetine for treating major depressive episodes
Vutrisiran 04.12 Formulary NICE TA868: Vutrisiran for treating hereditary transthyretin-related amyloidosis
Zanabrutinib 08.01.05 Formulary NICE TA931: Zanubrutinib for treating chronic lymphocytic leukaemia
Zanamivir 05.03.04 Formulary NICE TA168: Amantadine, oseltamivir and zanamivir for the treatment of influenza
Zanamivir 05.03.04 Formulary NICE TA158: Oseltamivir, amantadine (review) and zanamivir for the prophylaxis of influenza
Zanamivir Injection 05.03.04 Formulary NICE TA168: Amantadine, oseltamivir and zanamivir for the treatment of influenza
Zanamivir Injection 05.03.04 Formulary NICE TA158: Oseltamivir, amantadine (review) and zanamivir for the prophylaxis of influenza
Zanubrutinib 08.01.05 Formulary NICE TA833: Zanubrutinib for treating Waldenstrom’s macroglobulinaemia
Zoledronic Acid 5mg injection 06.06.02 Formulary NICE TA464 Bisphosphonates for treating osteoporosis
Zolpidem 04.01.01 Formulary NICE TA77: Zaleplon, zolpidem and zopiclone for the management of insomnia
Zopiclone 04.01.01 Formulary NICE TA77: Zaleplon, zolpidem and zopiclone for the management of insomnia
North East and North Cumbria